Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2022.09.08

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Commences recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments

Sai Life Sciences, today announced plans to grow the scientific team at its site in Manchester, UK by 20% and commenced the process of recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments. View open positions.

Making the announcement, Dr Dean Edney, Global Head of Process R&D at Sai Life Sciences said, “In a little over two years since we began in Manchester, our team has established a formidable reputation for itself as a high-quality scientific unit that can solve complex chemistry challenges. Our growing list of global innovator clients is a strong validation of our success. The present recruitment drive is aimed at increasing our scientific capacity to better serve the growing demand.”

In July 2020, Sai Life Sciences opened a new Centre of Excellence in Process Chemistry R&D in Alderley Park, Manchester to help accelerate the NCE development programmes of its global innovator customers. This Centre has since grown to become a reliable partner to many innovator companies across the world, providing high quality chemistry, non-GMP material delivery, and successful technology transfer to its sites in India for scale-up.

Now, with a growing interest from its customers for clinical API supplies from Manchester, work is underway to set-up a GMP Kilo Lab at the Manchester site. Scheduled to be commissioned in Q4-2022, the new facility will be capable of delivering GMP drug substance and intermediates, with the GMP equipment engineered to provide containment down to 1µg/m3.

As part of the SaiNxt transformation initiative, the company has executed investments of US$110M in expanding into new geographies, augmenting its capacity and operations, while raising the bar for quality, compliance and performance.

Share article

More News

2025.02.07

Sai Life Sciences headquarters, symbolizing innovation and growth, featured in a blog post about the company's strong quarterly report performance.

Sai Life Sciences Limited reports robust quarterly results

Revenue grows by 15%; Net Profit up 36% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research and Development Organization (CRDMO) today announced its financial results for the third quarter and nine months ended December 31, 2024. Financial Performance: Particulars (₹ crores) Q3FY25 Q3FY24 YoY% 9MFY25 9MFY24 YoY% Revenue […]
Read more

2025.01.01

Before and after comparison of the historic Manchirevula stepwell restoration by Sai Life Sciences, showcasing transformation from a neglected site to a well-maintained water body near a temple.

Sai Life Sciences completes restoration of historic Manchirevula stepwell

As part of its Corporate Social Responsibility (CSR) initiative, Sai Life Sciences, in collaboration with the Society for Advancement of Human Endeavours (SAHE), completed the restoration of the historic stepwell dating back to the 17th century at the Sri Venugopala Swamy temple premises, located in Manchirevula, Hyderabad. The Manchirevula Stepwell Restoration Project was undertaken with […]
Read more

2024.10.28

Advanced manufacturing facility at Sai Life Sciences, showcasing state-of-the-art equipment and quality control, featured in a blog post about receiving Establishment Inspection Reports (EIRs) from the USFDA.

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India. The General Good Manufacturing Practices (GMP) audit was conducted at the […]
Read more

2024.10.07

Sai Life Sciences' eco-friendly campus with green landscaping and modern architecture at sunset, featured in a blog post about the company's 2024 Sustainability Report

Sai Life Sciences releases Sustainability Report 2024

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], published its Sustainability Report for 2023-2024. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, this fifth edition of the Sustainability Report is based on the theme, ‘Synergising Sustainability, Performance and Growth.’ The full report can be read here. Making […]
Read more

2024.08.09

Sai Life Sciences scientist accessing a -40.2°C ultra-low temperature storage unit as part of the advanced Compound Management process, enhanced by the in-house CORAL software application.

Sai Life Sciences elevates Compound Management process with in-house software application, CORAL

Compound management is a vital function in pharmaceutical research. A streamlined environment can bring significant value to the process in the form of productivity and efficiency. Recognizing the importance of this function, we have made our Compound Management suite for Discovery services smarter with the introduction of an in-house software application, Compound Organization and Registration […]
Read more